Bluebird bio — Investor Day (June 2017)
35 slides from Bluebird bio's investor day presentation, Jun 5, 2017
Slide 1: bb2121 Investor & Analyst Event
bb2121 Investor & Analyst Event June 5, 2017 NASDAQ: BLUE Exhibit 99.1
Slide 2: Forward Looking Statements
These slides and the accompanying oral presentation contain forward-looking statements and information relating to bluebird bio, its product candidate bb2121 and oncology research and development plans. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “belie
Slide 3: Agenda
Agenda Introduction bluebird Oncology Franchise CRB-401 Study Design and Clinical Overview CRB-401 Data Closing Q&A Manisha Pai, Nick Leschly Philip Gregory, D.Phil. M. Travis Quigley Jesus Berdeja, M.D. David Davidson, M.D. bluebird bio management Jesus Berdeja, M.D., principal investigator Michael
Slide 4: Welcome
Welcome Nick Leschly, chief bluebird
Slide 5: Our Vision: Make Hope a Reality
Our Vision: Make Hope a Reality TRUE BLUE BLUE MOJO OUR PATIENTS OUR PEOPLE
Slide 6: Advancing Multiple Programs in Parallel
Advancing Multiple Programs in Parallel MM TDT SCD CALD
Slide 7: Our Strategic Intent
Our Strategic Intent Severe Genetic Diseases Hematopoietic Stem Cells (HSCs) Immunotherapy T Cells Late Stage (LentiGlobin, Lenti-D) Big Near Term Opportunities (SCD, Multiple Myeloma) Best Team (300+) Great Partners Truly Integrated Platform Transformative Product Focus “Tetris” R&D (Anti-Pure Play
Slide 8: bluebird Oncology Franchise
bluebird Oncology Franchise Philip Gregory, D.Phil., chief scientific officer
Slide 9: Pipeline
CNS Diseases Pipeline Lenti-D™ Drug Product Yet Rare Hemoglobinopathies Lentictobin’ (Phase 3) Worldwide Drug Product ee bb2121 Celgene bb21217 Celgene Oncology HPV-16 E6 TCR Kite Pharma Viromed Target fem eres Medigene Targets Worldwide Research Early Pipeline Undisclosed + Gene Editing Worldwide C
Slide 10: Good is Never Good Enough for Patients: bluebird Toolbox Strategy
Good is Never Good Enough for Patients: bluebird Toolbox Strategy BCMA (bb2121) LentiGlobin v1.0 Transduction Durability BCMA & PI3Ki (bb21217) LentiGlobin & Enhancers v2.0 Novel areas; autoimmune In vivo gene editing Optimized severe genetic disease products New & enhanced oncology products vFuture
Slide 11: Building a Translational Oncology Products Company
Building a Translational Oncology Products Company: The Right Approach for the Right Targets Targets Tools Partnerships Immuno-Oncology R&D Engine Oncology Pipeline Access to targets: both CARs and TCRs Optimization: gene editing; manufacturing enhancements; on/off switches; product and technology c
Slide 12: Tumor Specific Antigens e.g. Intracellular Targets
Tumor Specific Antigens e.g. Intracellular Targets TCR technology provides T cell redirection to intracellular antigens not addressable by CARs Medigene partnership provides bluebird access to TCR therapeutic candidates against four targets Targets Personalized cancer treatment with TCRs Rapid, effi
Slide 13: Building on the T Cell Chassis with Manufacturing Improvements and Genome Editing
Example 1: bb21217 – making younger T cells Example 2: megaTALs – driving site specific CAR insertion Tools Building on the T Cell Chassis with Manufacturing Improvements and Genome Editing
Slide 14: Building a Translational Oncology Products Company
Building a Translational Oncology Products Company: The Right Approach for the Right Targets Access to targets: both CARs and TCRs Optimization: gene editing; manufacturing enhancements; on/off switches; product and technology combinations Internal focus on bluebird strengths coupled with academic a
Slide 15: CRB-401 Study Design and Clinical Overview
CRB-401 Study Design and Clinical Overview M. Travis Quigley BCMA program leader & senior director, clinical development
Slide 16: Despite Progress in Multiple Myeloma, There Remains a Need for New Therapies
Despite Progress in Multiple Myeloma, There Remains a Need for New Therapies Kenneth C. Anderson Clin Cancer Res 2016;22:5419-5427 “Despite the availability of these classes of drugs for the treatment of MM, a recent analysis of patients with relapsed and refractory MM (RRMM) who were double refract
Slide 17: Current U.S. Standard of Care in 3rd/4th Line Multiple Myeloma
Current U.S. Standard of Care in 3rd/4th Line Multiple Myeloma Current U.S. Standards of Care Pomalyst and dex. (Pomalyst Product Monograph) Daratumamab (Lancet 2016, Lonial, S) N 452 106 Inclusion Criteria ≥2 prior therapies (including REVLIMID and bortezomib) Relapsed and refractory multiple myelo
Slide 18: BCMA – A Promising Target in Multiple Myeloma
BCMA – A Promising Target in Multiple Myeloma Multiple myeloma cells expressing BCMA (brown color = BCMA protein) BCMA is member of the TNF receptor superfamily expressed nearly universally on multiple myeloma cells with expression largely restricted to plasma cells and some mature B cells Initial p
Slide 19: Introduction to bb2121
Introduction to bb2121 bb2121 is a second-generation CAR construct targeting BCMA, consisting of autologous T cells transduced with a lentiviral vector encoding a novel CAR incorporating an anti-BCMA scFv, a 4-1BB costimulatory motif to promote proliferation and persistence, and a CD3-zeta T cell ac
Slide 20: CRB-401 Phase 1 Study in Relapsed / Refractory Multiple Myeloma
CRB-401 Phase 1 Study in Relapsed / Refractory Multiple Myeloma Objectives: Determine preliminary safety and efficacy and recommended phase 2 dose N = 50 patients, standard 3 + 3 dose escalation + expansion cohort Eligibility: Relapsed / refractory MM with ≥ 3 prior lines of therapy (including PI an
Slide 21: CRB-401 Data
CRB-401 Data Jesus Berdeja, M.D. Sarah Cannon Research Institute & Tennessee Oncology
Slide 22: First-in-Human Multicenter Study of bb2121 anti-BCMA CAR T Cell Therapy: Updated Results
First-in-Human Multicenter Study of bb2121 anti-BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma: Updated Results Jesus G. Berdeja, MD1, Yi Lin, MD, PhD2, Noopur Raje, MD3, Nikhil Munshi, MD4, David Siegel, MD, PhD5, Michaela Liedtke, MD6, Sundar Jagannath, MD7, Marcela Maus, MD, PhD
Slide 23: CRB-401 Open-label Phase 1 Clinical Study of bb2121
CRB-401 Open-label Phase 1 Clinical Study of bb2121 Study Status CRB-401 is a phase 1 dose-escalation and dose response study in relapsed / refractory MM Objectives: Determine preliminary safety and efficacy and recommended phase 2 dose 50 patients planned, standard 3 + 3 dose escalation followed by
Slide 24: Baseline Demographics, Clinical Characteristics and Treatment History
Baseline Demographics, Clinical Characteristics and Treatment History 21 patients have received bb2121 as of the data cut-off of May 4, 2017. Median follow-up is 15.4 weeks (range 1.4 to 54.4). 1 ECOG: Eastern Cooperative Oncology Group Performance Score 2 ISS: International Staging System 3 SCT: St
Slide 25: bb2121 Generally Well Tolerated
No dose-limiting toxicities (DLTs) observed as of data cut-off Cytopenias related to Cy/Flu lymphodepletion 1 unrelated death due to cardio pulmonary arrest in a patient with an extensive cardiac history, the event occurred over 4 months after bb2121 infusion. The patient had achieved a stringent CR
Slide 26: Cytokine Release Syndrome Readily Manageable
Cytokine Release Syndrome Readily Manageable 15/21 (71%) with cytokine release syndrome (CRS) 2 patients with Grade 3 CRS that resolved in 24 hours 4 patients received tocilizumab, 1 (Grade 2 CRS) with steroids CRS grade does not appear related to tumor burden CRS-related symptoms mostly Grade 1-2 N
Slide 27: All Patients in Active Dose Cohorts Achieved an Objective Response
All Patients in Active Dose Cohorts Achieved an Objective Response, Duration up to 54 Weeks * High tumor burden (>50% bone marrow involvement) Includes unscheduled assessments.
Slide 28: Clinical Response: Time to Response and MRD
Clinical Response: Time to Response and MRD Efficacy Parameter % (95% CI) ORR all doses 89% (65-99) ORR (> 50 x 106 CAR+ cells) 100% (78.2-100) ≥VGPR (> 50 x 106 CAR+ cells) 73% CR rate (> 50 x 106 CAR+ cells) 27% Median (range) Time to First Response (days) 31 (15-92) Time to Best Response (days) 5
Slide 29: Tumor Response Kinetics
Tumor Response Kinetics: Rapid Clearance of PET Uptake, sBCMA and sFLC; Slower Clearance of M-protein PET imaging Pt 8 dFLC (% change from baseline)* Serum M-protein (% change from baseline) Serum BCMA (% change from baseline)
Slide 30: Persistence of CAR T Cells in Peripheral Blood
Persistence of CAR T Cells in Peripheral Blood up to 24 Weeks
Slide 31: Summary
Summary bb2121 has induced durable and deepening responses in a heavily pre-treated population with relapsed/refractory multiple myeloma, including: 100% ORR, 73% VGPR or better, 27% CR (at doses > 50 x 106) MRD negative results in all evaluable patients (N=4) No disease progression in patients trea
Slide 32: Closing
Closing David Davidson, M.D., chief medical officer
Slide 33: Key Takeaways
Key Takeaways As of May 4 Data Cut-off No DLTs; toxicity readily manageable, CRS largely grade 1/2, two Grade 3 CRS resolved within 24 hours with tocilizumab Safety Profile Responses Durability 100% response rate in active dose cohorts (above 50x106) 27% complete response rate 73% VGPR or better All
Slide 34: Q&A
Q&A bluebirddio
Slide 35: Q&A
Q&A Nick Leschly, chief bluebird David Davidson, M.D., chief medical officer Philip Gregory, D.Phil., chief scientific officer M. Travis Quigley, BCMA program leader & senior director, clinical development Jesus Berdeja, M.D., Sarah Cannon Research Institute & Tennessee Oncology Michael Pehl, presid